Maynard Um
-
-
-
-
-
-
-
Vir Biotechnology (VIR) PT Raised to $20 at H.C. Wainwright
-
-
-
-
-
-
-
Astellas partners with Vir Biotechnology on prostate cancer treatment
-
-
-
-
-
-
-
VIR to present hepatitis delta trial results at liver meeting
-
-
-
-
-
-
-
Vir Biotechnology (VIR) PT Lowered to $15 at H.C. Wainwright
-
-
-
-
-
-
-
Vir Biotechnology (VIR) PT Raised to $14 at JPMorgan
-
-
-
-
-
-
-
Vir Biotechnology (VIR) Receives Positive Opinion on Orphan Drug Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta from European Medicines Agency
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Vir Biotechnology (VIR)
-
466,298 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


